[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Irja |
| 2. | Perekonnanimi | Lutsar |
| 3. | Töökoht | Tartu Ülikool, Mikrobioloogia Instituut |
| 4. | Ametikoht | Professor, Instituudi juhataja |
| 5. | Sünniaeg | 20.07.1954 (päev.kuu.aasta) |
| 6. | Haridus | Põhiharidus - Räpina Keskkool, 1972 MD - Tartu Ülikool, 1978 PhD - Tartu Ülikool, 1995 Post-dok laste nakkushaigustes - Southwestern Medical School, Dallas, Texas, USA, 1995-1998 |
| 7. | Teenistuskäik | 1978-79 Tallinna 1. Lastehaigla, intern 1979-82 pediaater,Võru Rajooni Keskhaigla 1982-92 peaarsti asetäitja ravi alal, nakkuskorpuse juhataja, Tartu Linna Kliiniline Lastehaigla 1992-95 nakkusosakonna juhataja, laste nakkushaiguste konsultant, Tartu Ülikooli Lastekliinik 1995-98 Fellow in paediatric infectious diseases, Southwestern Medical Center at Dallas, USA 1998-99 Assistent, nakkusbloki juhataja, Tartu Ülikooli Lastekliinik 1999-03 kliinilise projekti juht, Pfizer Ltd., Global Research and Development, UK 2003-04 pediaatrilise programmi juht. Pfizer Ltd, Sandwich, Inglismaa 2004- professor, TÜ mikrobioloogia instituudi juhataja |
| 8. | Teaduskraad | MD, PhD |
| 9. | Teaduskraadi välja andnud asutus, aasta |
Tartu, Ülikool 1995 |
| 10. | Tunnustused | Eesti Vabariigi Teaduspreemia (uurimisgrupi liige), 1994 European Society for Pediatric Infectious Diseases preemia uurimistööks, 1995 |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
Balti Lasteneuroloogide Assotsiatsiooni Esimene Konverents, Tartu 1991 peasekretär Balti Lasteneuroloogide Assotsiatsiooni Teine Konverents, Riia 1993 korralduskomitee liige Rahvusvaheline sümpoosium “Impact of the environment to children’s health” Tartu 1993, peasekretär Eesti Lastearstide Kongress, Tallinn 1989, Tallinn 1994 korralduskomitee liige Eesti Lastearstide Seltsi juhatuse liige aastatel 1990-1995 Eesti Infektsionistide Seltsi juhatuse liige aastatel 1992-1994, president 1998-1999 Balti Lasteneuroloogide Seltsi juhatuse liige aastatel 1990-1993 ESPID (European Society for Pediatric Infectious Diseases) teaduskomisjoni liige 2002-2005 |
| 12. | Juhendamisel kaitstud väitekirjad |
|
| 13. | Teadustöö põhisuunad | Neonataalse perioodi infektsioonid, patogeenees ning ravi Kesknärvisüsteemi infektsioonid lastel - patogenees, ravi ja kaugtulemused Antibiootikumide farmakokineetilised ja farmakodünaamilised omadused lastel HIV - rekombinantsete viiruste tähtsus haigusprotsessis |
| 14. | Jooksvad grandid | ESPID Small grant award 5000 EUR alates 01.09.2005 |
| 15. | Teaduspublikatsioonid |
Lutsar I. HI-viirusinfektsioon kui globaalne probleem. Eesti Arst 2005; 84: 238-243 Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O. Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases. Clin Infect Dis 2005; 40: 1141-7 Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Dodell B, Lutsar I, Troke P, Thiel E. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood 2005; 106: 2641-45 Usonis V, Meriste S, Bakasenas V, Lutsar I, Collard F, Stoffel M, Tornieporth N. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months Vaccine. 2005; 23: 2602-6 Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-98 Thiel E, Schwartz S, Ruhnke M, et al. Advances in the treatment of patients with central nervous system aspergillosis Bone Marrow Transplantation 2004; 33: S41-S41 Suppl. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intrevenous voriconazole in children after single and multiple dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72 E. Tamm, S. Kõljalg, I. Lutsar, M. Maimets, P. Naaber. Pneumokokkinfektsioon lapseeas. Eesti Arst, 2003, 7, 464-469 Lutsar I., Friedland I.R., Wubbel L., Ahmed A., Truijllo M., McCoig C.C., Jafri H.H., McCracken G.H.Jr. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2003; 52: 651-655 Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualisation. Clin Infect Dis 2003; 36: 1087-88 Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-32 Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, De La Torre-Cisneros J, Just-Nübling G, Schlamm H, Lutsar I, Espinel-Ingroff A, and Johnson E. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131 Walsh, TJ; Lutsar I, Driscoll, T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248 Lutsar, I; Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39: 335-343 Ng W, Olsen K, Lutsar I, Wubbel L, Ghaffar F, Jafri H, McCracken GH, Friedland I. Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia. APMIS, 2000; 108: 729-33 Perfect JR, Lutsar I, Gonzalez-Ruiz A. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. Clin Infect Dis 2000; 31: 303 Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, et al. Voriconazole (VORI) for the treatment of S-apiospermum and S-prolificans infection. Clin Infect Dis 2000; 21: 305 Ahmed A., Jafri H., Lutsar I., McCoig C.C., Trujillo M., Wubbel L., Shelton S., McCracken G.H. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999; 43:876-881 Lutsar I., Friedland I.R., Jafri H.S., Wubbel L., Ng W., Ghaffar F., McCracken G.H. Jr. Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother, 1999; 43: 1805-07 McCoig C.C., Friedland I.R., Lutsar I., Jafri H.S., Wubbel L., Olsen K., Shelton S., McCracken G.H.Jr. Pharmacodynamics and bactericidal activity of trovafloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 1999; 43: 683-688 Meriste S., Tamm E., Willems P., Lutsar I. Safety and immunogenicity of combined DTPa-IPV for primary and booster vaccination. Scand J Inf Dis 1999; 31:587-591 Ng W., Lutsar I., Wubbel L., Jafri H., Ghaffar F., McCracken G.H.Jr., Friedland I.R. Pharmacodynamics of trovafloxacin in the cephalosporin-resistant pneumococcal pneumonia in immunocompetent mice. J Antimicrob Chemother, 1999; 43:811-816 Friedland I.R., Lutsar I. New Antibiotics. Current Opinion in Pediatrics 1998; 10: 41-45. Lutsar I., Friedland I.R., Wubbel L., McCoig C.C., Jafri H.S., Ng W., Ghaffar F., McCracken G.H.Jr. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42: 2650-2655 Lutsar I., McCracken G.H.Jr., Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis, 1998; 27: 1117-29 Lutsar I., Ahmed A., Friedland I.R., Trujillo M., Wubbel L., Olsen K., McCracken G.H. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1997; 41: 2414-2417 Lutsar I., Friedland I.R., McCracken G.H.Jr. Pathogenesis of bacterial meningitis. Annales Nestle 1997; 55: 92-102 Ahmed A, Trujillo M, Wubbel L, et al. Pharmacodynamics of vancomycin in experimental cephalosporin-resistant pneumococcal meningitis. Clin Infect Dis 1996; 23: 161-161 Siigur U., Tamm E., Torm S., Lutsar I., Salminen S. Effect of bacterial infection and administration of a probiotic on fecal short-chain fatty acids. Microbial Ecology in Health and Disease 1996; 9: 271-277 Lutsar I., Gontmacher A., Närska M., Rüütel V., Topman M., Ilves P., Siirde T., Beilmann A. Five days of antibacterial therapy for bacterial meningitis in children. Infection 1995; 23: 113-118 Lutsar I., Siirde T., Soopold T. Long term follow-up of Estonian children after bacterial meningitis. Pediatr Infect Dis J 1995;14:624-625 Lutsar I., Haldre S., Topman M., Talvik T. Enzymatic changes in cerebrospinal fluid in patients with infections of the central nervous system. Acta Pediatr 1994; 83: 1146-1150 Lutsar I, Narska M, Gontmacher A, et al. Cerebrospianl fluid IL-6 levels in children with and without infections of the central nervous system. Pediatric Research 1994; 36: a59-a59 |
viimati muudetud: 05.08.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Irja |
| 2. | Surname | Lutsar |
| 3. | Institution | University of Tartu, Department of Microbiology |
| 4. | Position | Professor, Head of Department |
| 5. | Date of birth | 20.07.1954 (day.month.year) |
| 6. | Education | MD - University of Tartu, 1978 PhD - University of Tartu, 1995 Reasearch Fellow in Paediatric Infectious Diseases - Southwestern Medical School, Dallas, Texas, USA, 1995-1998 |
| 7. | Research and professional experience |
1978-79 Internship in pediatrics, First Children’s Hospital, Tallinn, Estonia 1979-82 Pediatrician, Võru Hospital, Estonia 1982-92 Deputy Head of the Pediatric Hospital,Tartu University Children’s Hospital, Estonia 1992-95 Head of Pediatric Infectious Diseases Department, Consultant in pediatric Infectious diseases, Tartu University Children’s Hospital, Estonia 1995-98 Fellow in paediatric infectious diseases, Southwestern Medical Center at Dallas, USA 1998-99 Associated Professor in Pediatrics, Tartu University, Faculty of Medicine, Pediatric Department 1999-03 Clinical Project Manager, Pfizer Ltd., Global Research and Development, UK 2003-04 Director, Pfizer Ltd., Global Research and Development, UK 2004- Professor, Head of the Department of Medical Microbiology University of Tartu, Estonia |
| 8. | Academic degree | MD, PhD |
| 9. | Dates and sites of earning the degrees |
University of Tartu, 1995 |
| 10. | Honours/awards | Estonian Government award in medical science, 1994 European Society for Pediatric Infectious Diseases fellowship award, 1995 |
| 11. | Research-administrative experience |
1st International Meeting of Baltic Association of Child Neurology, Tartu 1991, secretary general 2nd International Meeting of Baltic Association of Child Neurology, Riga 1993, member of organizing committee International symposium Impact of the environment to children’s health, Tartu 1993, secretary general Congress of Estonian Pediatric Association, Tallinn 1989, Tallinn 1994, member of organizing committee Estonian Pediatric Association, Board member 1990-1995 Estonian Infectious Diseases Society, Board member 1992-1994 & 1998-1999 Baltic Association of Child Neurology, Board member 1990-1993 European Society for Pediatric Infectious Diseases, Member of scientific committee 2002-2005 |
| 12. | Supervised dissertations | |
| 13. | Current research program | Infections in neonates, their pathogenesis and management Infections of the central nervous system in children, their pathogenesis, treatment and long term outcome Pharmacokinetic and pharmacodynamic properties of antiinfective agents in children HIV infection, the importance of recombinant viruses in the disease process |
| 14. | Current grant funding | ESPID Small grant award 5000 EUR since 01.09.2005 |
| 15. | List of most important publications |
Lutsar I. HI-viirusinfektsioon kui globaalne probleem. Eesti Arst 2005; 84: 238-243 Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O. Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases. Clin Infect Dis 2005; 40: 1141-7 Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Dodell B, Lutsar I, Troke P, Thiel E. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood 2005; 106: 2641-45 Usonis V, Meriste S, Bakasenas V, Lutsar I, Collard F, Stoffel M, Tornieporth N. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months Vaccine. 2005; 23: 2602-6 Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-98 Thiel E, Schwartz S, Ruhnke M, et al. Advances in the treatment of patients with central nervous system aspergillosis Bone Marrow Transplantation 2004; 33: S41-S41 Suppl. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intrevenous voriconazole in children after single and multiple dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72 E. Tamm, S. Kõljalg, I. Lutsar, M. Maimets, P. Naaber. Pneumokokkinfektsioon lapseeas. Eesti Arst, 2003, 7, 464-469 Lutsar I., Friedland I.R., Wubbel L., Ahmed A., Truijllo M., McCoig C.C., Jafri H.H., McCracken G.H.Jr. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2003; 52: 651-655 Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualisation. Clin Infect Dis 2003; 36: 1087-88 Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-32 Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, De La Torre-Cisneros J, Just-Nübling G, Schlamm H, Lutsar I, Espinel-Ingroff A, and Johnson E. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131 Walsh, TJ; Lutsar I, Driscoll, T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248 Lutsar, I; Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39: 335-343 Ng W, Olsen K, Lutsar I, Wubbel L, Ghaffar F, Jafri H, McCracken GH, Friedland I. Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia. APMIS, 2000; 108: 729-33 Perfect JR, Lutsar I, Gonzalez-Ruiz A. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. Clin Infect Dis 2000; 31: 303 Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, et al. Voriconazole (VORI) for the treatment of S-apiospermum and S-prolificans infection. Clin Infect Dis 2000; 21: 305 Ahmed A., Jafri H., Lutsar I., McCoig C.C., Trujillo M., Wubbel L., Shelton S., McCracken G.H. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999; 43:876-881 Lutsar I., Friedland I.R., Jafri H.S., Wubbel L., Ng W., Ghaffar F., McCracken G.H. Jr. Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother, 1999; 43: 1805-07 McCoig C.C., Friedland I.R., Lutsar I., Jafri H.S., Wubbel L., Olsen K., Shelton S., McCracken G.H.Jr. Pharmacodynamics and bactericidal activity of trovafloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 1999; 43: 683-688 Meriste S., Tamm E., Willems P., Lutsar I. Safety and immunogenicity of combined DTPa-IPV for primary and booster vaccination. Scand J Inf Dis 1999; 31:587-591 Ng W., Lutsar I., Wubbel L., Jafri H., Ghaffar F., McCracken G.H.Jr., Friedland I.R. Pharmacodynamics of trovafloxacin in the cephalosporin-resistant pneumococcal pneumonia in immunocompetent mice. J Antimicrob Chemother, 1999; 43:811-816 Friedland I.R., Lutsar I. New Antibiotics. Current Opinion in Pediatrics 1998; 10: 41-45. Lutsar I., Friedland I.R., Wubbel L., McCoig C.C., Jafri H.S., Ng W., Ghaffar F., McCracken G.H.Jr. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42: 2650-2655 Lutsar I., McCracken G.H.Jr., Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis, 1998; 27: 1117-29 Lutsar I., Ahmed A., Friedland I.R., Trujillo M., Wubbel L., Olsen K., McCracken G.H. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1997; 41: 2414-2417 Lutsar I., Friedland I.R., McCracken G.H.Jr. Pathogenesis of bacterial meningitis. Annales Nestle 1997; 55: 92-102 Ahmed A, Trujillo M, Wubbel L, et al. Pharmacodynamics of vancomycin in experimental cephalosporin-resistant pneumococcal meningitis. Clin Infect Dis 1996; 23: 161-161 Siigur U., Tamm E., Torm S., Lutsar I., Salminen S. Effect of bacterial infection and administration of a probiotic on fecal short-chain fatty acids. Microbial Ecology in Health and Disease 1996; 9: 271-277 Lutsar I., Gontmacher A., Närska M., Rüütel V., Topman M., Ilves P., Siirde T., Beilmann A. Five days of antibacterial therapy for bacterial meningitis in children. Infection 1995; 23: 113-118 Lutsar I., Siirde T., Soopold T. Long term follow-up of Estonian children after bacterial meningitis. Pediatr Infect Dis J 1995;14:624-625 Lutsar I., Haldre S., Topman M., Talvik T. Enzymatic changes in cerebrospinal fluid in patients with infections of the central nervous system. Acta Pediatr 1994; 83: 1146-1150 Lutsar I, Narska M, Gontmacher A, et al. Cerebrospianl fluid IL-6 levels in children with and without infections of the central nervous system. Pediatric Research 1994; 36: a59-a59 |
last updated: 05.08.2005
[ sulge aken ]